Asset
Sabirnetug
Acumen Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04931459 | phase1 | completed | 2021-06-21 | 2023-06-12 | Acumen Pharmaceuticals | A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD |
FDA applications (0)
This company has no applications containing this asset.